Anabolic therapies

Nancy E Lane, Stuart L. Silverman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

Original languageEnglish (US)
Pages (from-to)23-27
Number of pages5
JournalCurrent Osteoporosis Reports
Volume8
Issue number1
DOIs
StatePublished - Mar 2010

Fingerprint

Parathyroid Hormone-Related Protein
Teriparatide
Anabolic Agents
Bone Morphogenetic Proteins
United States Food and Drug Administration
Subcutaneous Injections
Parathyroid Hormone
Osteoporosis
Monoclonal Antibodies
Hormones
Therapeutics

Keywords

  • BMD
  • BMP
  • Osteoporosis
  • PTH
  • Sclerostin
  • Wnt

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Anabolic therapies. / Lane, Nancy E; Silverman, Stuart L.

In: Current Osteoporosis Reports, Vol. 8, No. 1, 03.2010, p. 23-27.

Research output: Contribution to journalArticle

Lane, Nancy E ; Silverman, Stuart L. / Anabolic therapies. In: Current Osteoporosis Reports. 2010 ; Vol. 8, No. 1. pp. 23-27.
@article{d1e0662e33ca493ab2a0a0111465f63f,
title = "Anabolic therapies",
abstract = "The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.",
keywords = "BMD, BMP, Osteoporosis, PTH, Sclerostin, Wnt",
author = "Lane, {Nancy E} and Silverman, {Stuart L.}",
year = "2010",
month = "3",
doi = "10.1007/s11914-010-0005-4",
language = "English (US)",
volume = "8",
pages = "23--27",
journal = "Foodborne Pathogens and Disease",
issn = "1744-165X",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Anabolic therapies

AU - Lane, Nancy E

AU - Silverman, Stuart L.

PY - 2010/3

Y1 - 2010/3

N2 - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

AB - The striking clinical benefits of intermittent parathyroid hormone in osteoporosis have begun a new era of skeletal anabolic agents. Recombinant human parathyroid hormone (rhPTH) (1-34) is the first US Food and Drug Administration-approved anabolic therapy. Its use has been limited by the need for subcutaneous injection. Newer delivery systems include transdermal and oral preparations. Newer anabolic therapies include monoclonal antibody to sclerostin, a potent inhibitor of osteoblastogenesis; and use of bone morphogenetic proteins and parathyroid hormone-related protein PTHrP, a calciumregulating hormone similar to PTH.

KW - BMD

KW - BMP

KW - Osteoporosis

KW - PTH

KW - Sclerostin

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=77953621455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953621455&partnerID=8YFLogxK

U2 - 10.1007/s11914-010-0005-4

DO - 10.1007/s11914-010-0005-4

M3 - Article

C2 - 20425087

AN - SCOPUS:77953621455

VL - 8

SP - 23

EP - 27

JO - Foodborne Pathogens and Disease

JF - Foodborne Pathogens and Disease

SN - 1744-165X

IS - 1

ER -